强化收缩压控制与糖尿病及非糖尿病人群新发慢性肾病:两项随机对照试验的二次分析
该研究对SPRINT和ACCORD试验进行二次分析,比较强化与标准收缩压控制对新发慢性肾病的影响。结果显示,在糖尿病和非糖尿病人群中,强化降压均增加新发慢性肾病风险,但糖尿病人群的绝对风险更高。作者建议在强化降压治疗期间警惕肾功能监测,尤其对糖尿病成人。
要点
- 强化降压在糖尿病和非糖尿病人群均增加新发慢性肾病风险
- 糖尿病患者的绝对风险差为5.9%,高于非糖尿病人群的2.5%
- 糖尿病成人强化降压治疗期间需警惕肾功能监测
核心结论
- 强化降低收缩压增加糖尿病和非糖尿病人群新发慢性肾病风险,但糖尿病患者的绝对风险更高,提示强化降压治疗期间需警惕肾功能监测,尤其对糖尿病成人。
研究设计与样本
- 二次分析SPRINT和ACCORD试验数据,纳入基线无慢性肾病者:ACCORD 4311例,SPRINT 6715例。
- SPRINT在无糖尿病人群中比较收缩压目标<120 mmHg与<140 mmHg;ACCORD在2型糖尿病人群中测试类似干预。
主要发现
- 强化与标准干预的平均收缩压差:ACCORD为13.9 mmHg(95% CI 13.4-14.4),SPRINT为15.2 mmHg(14.8-15.6)。
- 3年时新发慢性肾病累积发生率:ACCORD强化组10.0%(95% CI 8.8-11.4) vs 标准组4.1%(3.3-5.1),绝对风险差5.9%(95% CI 4.3-7.5)。
- SPRINT强化组3.5%(95% CI 2.9-4.2) vs 标准组1.0%(0.7-1.4),绝对风险差2.5%(95% CI 1.8-3.2)。
- 绝对风险差在ACCORD试验中显著高于SPRINT(交互作用p=0.0001)。
关键数值与推荐
- 新发慢性肾病定义为eGFR下降>30%至<60 mL/min per 1.73 m²。
临床怎么用
- 作者认为,强化降压治疗期间需警惕肾功能监测,尤其对糖尿病成人。
- 作者建议需长期研究以理解降压治疗相关eGFR降低的临床意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines, including the 2017 American College of Cardiology and American Heart Association blood pressure guideline, recommend tighter control of systolic blood pressure in people with type 2 diabetes. However, it is unclear whether intensive lowering of systolic blood pressure increases the incidence of chronic kidney disease in this population. We aimed to compare the effects of intensive systolic blood pressure control on incident chronic kidney disease in people with and without type 2 diabetes. METHODS: The Systolic Blood Pressure Intervention Trial (SPRINT) tested the effects of a systolic blood pressure goal of less than 120 mm Hg (intensive intervention) versus a goal of less than 140 mm Hg (standard intervention) in people without diabetes. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) blood pressure trial tested a similar systolic blood pressure intervention in people with type 2 diabetes. Our study is a secondary analysis of limited access datasets from SPRINT and the ACCORD trial obtained from the National Institutes of Health. In participants without chronic kidney disease at baseline (n=4311 in the ACCORD trial; n=6715 in SPRINT), we related systolic blood pressure interventions (intensive vs standard) to incident chronic kidney disease (defined as >30% decrease in estimated glomerular filtration rate [eGFR] to <60 mL/min per 1·73 m2). These trials are registered with ClinicalTrials.gov, numbers NCT01206062 (SPRINT) and NCT00000620 (ACCORD trial). FINDINGS: The average difference in systolic blood pressure between intensive and standard interventions was 13·9 mm Hg (95% CI 13·4-14·4) in the ACCORD trial and 15·2 mm Hg (14·8-15·6) in SPRINT. At 3 years, the cumulative incidence of chronic kidney disease in the ACCORD trial was 10·0% (95% CI 8·8-11·4) with the intensive intervention and 4·1% (3·3-5·1) with the standard intervention (absolute risk difference 5·9%, 95% CI 4·3-7·5). Corresponding values in SPRINT were 3·5% (95% CI 2·9-4·2) and 1·0% (0·7-1·4; absolute risk difference 2·5%, 95% CI 1·8-3·2). The absolute risk difference was significantly higher in the ACCORD trial than in SPRINT (p=0·0001 for interaction). INTERPRETATION: Intensive lowering of systolic blood pressure increased the risk of incident chronic kidney disease in people with and without type 2 diabetes. However, the absolute risk of incident chronic kidney disease was higher in people with type 2 diabetes. Our findings suggest the need for vigilance in monitoring kidney function during intensive antihypertensive drug treatment, particularly in adults with diabetes. Long-term studies are needed to understand the clinical implications of antihypertensive treatment-related reductions in eGFR. FUNDING: National Institutes of Health.
引用
- Beddhu S, Greene T, Boucher R, et al. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol. 2018. PMID: 29685860. doi:10.1016/S2213-8587(18)30099-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。